AITC is also associated with reduced inflammation in diseases such as osteoarthritis, inflammatory bowel disease, and obesity-induced inflammation, contributing to the activation of the transient receptor potential ankyrin 1 (TRPA1), ERK signaling, and the inhibition of monocyte chemoattractant protein-1 (MCP-1) [59,60,61]. This evidence concerns the gene TRPA1 and inflammatory bowel disease.